165 related articles for article (PubMed ID: 19010932)
1. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability.
Xue Q; Hopkins B; Perruzzi C; Udayakumar D; Sherris D; Benjamin LE
Cancer Res; 2008 Nov; 68(22):9551-7. PubMed ID: 19010932
[TBL] [Abstract][Full Text] [Related]
2. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
3. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor.
Syed F; Sherris D; Paus R; Varmeh S; Singh S; Pandolfi PP; Bayat A
Am J Pathol; 2012 Nov; 181(5):1642-58. PubMed ID: 22982188
[TBL] [Abstract][Full Text] [Related]
4. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
5. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
6. The role of PI3K/Akt/mTOR signaling in dose-dependent biphasic effects of glycine on vascular development.
Tsuji-Tamura K; Sato M; Fujita M; Tamura M
Biochem Biophys Res Commun; 2020 Aug; 529(3):596-602. PubMed ID: 32736679
[TBL] [Abstract][Full Text] [Related]
7. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
Newton HB
Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
[TBL] [Abstract][Full Text] [Related]
8. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X
Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351
[TBL] [Abstract][Full Text] [Related]
9. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
10. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
Schnell CR; Stauffer F; Allegrini PR; O'Reilly T; McSheehy PM; Dartois C; Stumm M; Cozens R; Littlewood-Evans A; García-Echeverría C; Maira SM
Cancer Res; 2008 Aug; 68(16):6598-607. PubMed ID: 18701483
[TBL] [Abstract][Full Text] [Related]
11. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
12. Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb.
Good DW; George T; Watts BA
J Biol Chem; 2008 Sep; 283(39):26602-11. PubMed ID: 18660503
[TBL] [Abstract][Full Text] [Related]
13. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
15. The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation.
Ferguson KT; Torr EE; Bernau K; Leet J; Sherris D; Sandbo N
J Cell Biochem; 2017 Aug; 118(8):2241-2249. PubMed ID: 28078713
[TBL] [Abstract][Full Text] [Related]
16. Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway.
Haribalaganesh R; Sheikpranbabu S; Banumathi E; Gurunathan S
Exp Eye Res; 2010 Jun; 90(6):726-33. PubMed ID: 20298690
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Chaisuparat R; Hu J; Jham BC; Knight ZA; Shokat KM; Montaner S
Cancer Res; 2008 Oct; 68(20):8361-8. PubMed ID: 18922908
[TBL] [Abstract][Full Text] [Related]
18. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
19. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
20. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]